Your browser is no longer supported. Please, upgrade your browser.
Settings
ENTX Entera Bio Ltd. daily Stock Chart
ENTX [NASD]
Entera Bio Ltd.
Index- P/E- EPS (ttm)-1.01 Insider Own46.55% Shs Outstand11.52M Perf Week-12.33%
Market Cap37.67M Forward P/E- EPS next Y-0.99 Insider Trans- Shs Float5.02M Perf Month11.79%
Income-10.30M PEG- EPS next Q- Inst Own14.80% Short Float0.01% Perf Quarter-25.51%
Sales0.50M P/S75.34 EPS this Y8.80% Inst Trans3.77% Short Ratio0.04 Perf Half Y-34.47%
Book/sh1.27 P/B2.57 EPS next Y9.20% ROA- Target Price12.00 Perf Year-
Cash/sh1.00 P/C3.28 EPS next 5Y- ROE- 52W Range2.55 - 7.60 Perf YTD7.21%
Dividend- P/FCF- EPS past 5Y- ROI-107.50% 52W High-57.89% Beta-
Dividend %- Quick Ratio7.00 Sales past 5Y- Gross Margin- 52W Low25.49% ATR0.38
Employees19 Current Ratio7.00 Sales Q/Q- Oper. Margin- RSI (14)33.80 Volatility6.63% 11.42%
OptionableNo Debt/Eq0.00 EPS Q/Q14.10% Profit Margin- Rel Volume0.80 Prev Close3.27
ShortableYes LT Debt/Eq0.00 EarningsJun 27 BMO Payout- Avg Volume9.26K Price3.20
Recom- SMA20-11.87% SMA50-17.63% SMA200-28.04% Volume1,736 Change-2.14%
Mar-28-19 07:00AM  Entera Bio Reports 2018 Annual Financial Results and Operating Update GlobeNewswire
07:00AM  Entera Bio Announces 20-F Filing GlobeNewswire
Mar-27-19 11:02AM  Entera Bio to Announce Fourth Quarter and Year Ended December 31, 2018 Financial Results on Thursday, March 28 GlobeNewswire
Mar-07-19 07:00AM  Entera Bio Announces a Transition in the Chief Financial Officer Position GlobeNewswire
Jan-31-19 08:00AM  Entera Bio Announces Positive Feedback and Guidance from the US FDA Regarding its Development Plans for Oral PTH in Osteoporosis GlobeNewswire
Jan-22-19 08:00AM  Entera Bio Reports Third Quarter 2018 Financial Results and Operating Update GlobeNewswire -5.95%
Jan-10-19 07:00AM  Entera Bio Appoints Gerald M. Ostrov to Board of Directors GlobeNewswire -5.51%
Dec-11-18 09:32AM  Entera shares jump 11.5% on news of collaboration with Amgen MarketWatch -10.93%
07:00AM  Entera Bio and Amgen Enter Strategic Research Collaboration in Inflammatory Disease and Other Serious Illnesses GlobeNewswire
Nov-08-18 08:00AM  Entera Bio Reports Positive Results from Part 1 of a Phase 2 PK/PD Study of Oral PTH (1-34) in Patients with Hypoparathyroidism GlobeNewswire -7.89%
Oct-02-18 08:00AM  Entera Bio Appoints Two New External Independent Members to the Board of Directors GlobeNewswire +12.65%
Sep-21-18 09:15AM  Entera Bio Appoints Dr. Arthur Santora as Chief Medical Officer GlobeNewswire
Aug-20-18 04:05PM  Entera Bio Reports Second Quarter 2018 Financial Results and Operating Update GlobeNewswire
Aug-09-18 12:00PM  Entera Bio Ltd. Announces Appointment of Mr. Gerald Lieberman as Chairman of the Board of Directors GlobeNewswire
Aug-01-18 08:00AM  Entera Bio Completes Part 1 of a Phase 2 PK/PD Study in Hypoparathyroidism Patients GlobeNewswire +7.34%
Jul-02-18 04:05PM  Entera Bio Ltd. Announces Closing of Initial Public Offering GlobeNewswire +5.56%
Jun-28-18 08:53AM  Entera Bio Ltd. Announces Pricing of Initial Public Offering GlobeNewswire
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product includes the EB612, an oral parathyroid hormone product candidate that has completed a Phase IIa clinical trial for hypoparathyroidism. It is also developing EB613 that has completed Phase I clinical trials for the treatment of osteoporosis and non-union bone fractures; and other platform modules. The company was founded in 2010 and is headquartered in Jerusalem, Israel. Entera Bio Ltd. operates as a subsidiary of D.N.A Biomedical Solutions Ltd.